N-Acetyl Semax Amidate 30mg
The Most Potent Semax Variant for Peak Nootropic Research
N-Acetyl Semax Amidate is the most bioavailable and longest-acting form of the ACTH-derived nootropic Semax, enhancing BDNF, NGF, and VEGF expression in the brain while providing significant cognitive enhancement, neuroprotection, and anti-stroke effects in research models.
The Most Potent Semax Variant for Peak Nootropic Research
Semax is an ACTH(4-7) analogue developed in Russia as a nootropic drug. The N-acetyl amidate modification protects both termini from degradation, dramatically increasing half-life. Research shows it upregulates BDNF, enhances dopaminergic and serotonergic tone, and is neuroprotective in ischemia models.
As one of the most studied compounds in the longevity research space, Semax has attracted sustained scientific interest across Cognitive enhancement research, Neuroprotection studies, BDNF pathway research. Peer-reviewed evidence indicates that approved nootropic drug in Russia, which has positioned Semax as a reference standard for researchers exploring cognitive enhancement research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Semax Documented Benefits: 4 Documented Mechanisms
BDNF Upregulation
Increases brain-derived neurotrophic factor expression in the hippocampus and cortex, supporting neuroplasticity.
Cognitive Enhancement
Improves memory, learning, and attention in studies, with documented use as a prescribed nootropic in Russia.
Neuroprotection
Protects neurons from ischemic damage in stroke models and reduces neuroinflammation.
Enhanced Stability
N-acetyl amidate modification extends half-life dramatically vs. standard Semax.
How Semax Works: Molecular Mechanism & Pathway
ACTH(4-7)Pro-Gly-Pro analogue activating MC4R and BDNF/NGF/VEGF gene expression pathways in the CNS while modulating dopaminergic and serotonergic neurotransmission.
The 4 primary research pathways identified for Semax — BDNF Upregulation, Cognitive Enhancement, Neuroprotection — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that increases BDNF by 1.6x in rat hippocampus, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Semax's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Semax is routinely studied alongside P21 and Adamax in longevity-focused compound panels. Researchers investigating cognitive enhancement research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that neuroprotective in cerebral ischemia models has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Semax research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Approved nootropic drug in Russia
- Increases BDNF by 1.6x in rat hippocampus
- Neuroprotective in cerebral ischemia models
Ideal For
- Cognitive enhancement research
- Neuroprotection studies
- BDNF pathway research
- Stroke model research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Semax. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Approved nootropic drug in Russia
Increases BDNF by 1.6x in rat hippocampus
Neuroprotective in cerebral ischemia models
Third-Party Verified Every Batch
Each vial of Semax is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
